News & Articles

Elecsys pTau217 is the first single-assay blood test designed to identify or rule out amyloid pathology across primary and secondary care

Acquisition strengthens Roche’s digital pathology and companion diagnostic portfolio to advance precision medicine

How Roche and Disease Management Consulting empower laboratory professionals to drive strategic value in healthcare systems

Minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods

The cobas c 703 and cobas ISE neo analytical units deliver higher testing capacity and increased automation, helping to improve laboratory workflows and advance patient care

The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients

Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences

The point-of-care test detects and differentiates between three types of Bordetella infection that can cause similar cough symptoms, ensuring patients receive the right diagnosis at the earliest opportunity

This tool will be launched as part of Roche’s new chronic kidney disease algorithm panel to support care across the stages of the disease which affects 700 million people globally

Roche has been recognized as No. 1 in seven of nine award categories

Elecsys pTau181 is the first in vitro diagnostic regulation (IVDR)-certified test to rule out Alzheimer’s associated amyloid pathology

Data to be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress

Survey finds fear and misconceptions around hepatitis discourage testing, with more than half of respondents assuming they are not at risk

First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT)

Clinical mass spectrometry testing offers sensitivity and specificity, providing clinicians with additional diagnostic insights

The PATHWAY HER2 (4B5) test helps identify patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA

Roche’s Elecsys Amyloid Plasma Panel shows high accuracy in ruling out Alzheimer's, offering new hope for early and less invasive diagnostics

Roche obtains CE certification for VENTANA CLDN18 (43-14A) RxDx Assay to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

OCREVUS ZUNOVO has the potential to expand treatment options to centers without IV infrastructure or with IV constraints

The cobas c 703 and cobas ISE neo analytical units deliver greater efficiency and capacity to laboratories

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

The Roche Diagnostics Tina-quant Lp(a) assay measures lipoprotein (a) in a person’s bloodstream

Expanding access and screening options to help eliminate cervical cancer with one of the first HPV self-collection solutions in the US

Supporting earlier Alzheimer's disease diagnosis